肝硬化脓毒症患者白蛋白给药指征的识别
该研究基于MIMIC-IV 2.0数据库纳入2265例肝硬化脓毒症患者,其中1093例(48.3%)至少接受过一次白蛋白治疗,总体28天死亡率为29.6%。采用边际结构Cox模型分析发现,每日白蛋白输注与28天死亡风险降低相关(HR 0.76,95%CI 0.61–0.94)。进一步分析显示,在血清白蛋白2.5–3.0 g/dL、乳酸≥2 mmol/L、MAP<60 mmHg或升压药剂量0.2–0.3 mcg/kg/min(去甲肾上腺素等效)的当日启动白蛋白治疗,患者获益最大。作者认为血清白蛋白、乳酸、MAP和升压药剂量是治疗效果的效应修饰因子,决定是否启动白蛋白输注时应予以考虑。
要点
- 每日白蛋白输注与肝硬化脓毒症患者28天死亡风险降低相关(HR 0.76,95%CI 0.61–0.94)。
- 血清白蛋白2.5–3.0 g/dL当日启动白蛋白输注的患者获益最大。
- 血清乳酸≥2 mmol/L当日启动白蛋白输注的患者获益最大。
- MAP<60 mmHg或升压药剂量0.2–0.3 mcg/kg/min(去甲肾上腺素等效)当日启动白蛋白输注的患者获益最大。
- 作者认为血清白蛋白、乳酸、MAP和升压药剂量是治疗效果的效应修饰因子,决定启动白蛋白输注时应考虑这些指标。
适用人群与场景
- 来自MIMIC-IV 2.0数据库的肝硬化脓毒症患者,最终分析共纳入2265例。
处置流程与药物剂量
- 每日白蛋白输注与28天死亡风险降低相关(HR 0.76,95%CI 0.61–0.94)。
- 在血清白蛋白浓度2.5–3.0 g/dL的当日启动白蛋白输注,患者获益最大。
- 在血清乳酸浓度≥2 mmol/L的当日启动白蛋白输注,患者获益最大。
- 在MAP<60 mmHg的当日启动白蛋白输注,患者获益最大。
- 在升压药剂量0.2–0.3 mcg/kg/min(去甲肾上腺素等效,NEE)的当日启动白蛋白输注,患者获益最大。
研究设计与关键结果
- 研究类型:基于MIMIC-IV 2.0数据库的队列研究;样本量2265例;1093例(48.3%)至少接受过一次白蛋白治疗;总体28天死亡率为29.6%。
- 采用边际结构Cox模型分析,每日白蛋白输注与28天死亡风险降低相关(HR 0.76,95%CI 0.61–0.94)。
- 基于白蛋白输注当日临床参数分析,血清白蛋白浓度2.5–3.0 g/dL、血清乳酸≥2 mmol/L、MAP<60 mmHg或升压药剂量0.2–0.3 mcg/kg/min(去甲肾上腺素等效)时启动白蛋白输注,患者获益最大。
证据类型、等级与局限
- 证据类型:基于MIMIC-IV 2.0数据库的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血清白蛋白浓度、血清乳酸、MAP和升压药剂量是治疗效果的效应修饰因子,决定是否启动白蛋白输注时应予以考虑。
- 在肝硬化脓毒症患者中,当日血清白蛋白2.5–3.0 g/dL、乳酸≥2 mmol/L、MAP<60 mmHg或升压药剂量0.2–0.3 mcg/kg/min(去甲肾上腺素等效)时,可考虑启动每日白蛋白输注(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Albumin infusion is the primary therapeutic strategy for septic patients with liver cirrhosis. Although recent studies have investigated the efficacy of albumin in the resuscitation stage of septic patients with liver cirrhosis, it remains unclear whether daily albumin administration can improve outcomes. Furthermore, the indications for initiating albumin therapy are not well defined.
METHODS: Septic patients with liver cirrhosis were obtained from the Medical Information Mart for Intensive Care (MIMIC-IV 2.0) database. Marginal structural Cox models were employed to investigate the association between daily albumin infusion and 28-day mortality. We also aimed to explore under what circumstances enrolled patients could benefit most from albumin administration, based on the clinical parameters collected on the day of albumin infusion, including serum albumin concentration, serum lactate concentration, mean arterial pressure (MAP), and vasopressor dosage.
RESULTS: A total of 2265 patients were included in the final analysis, of whom 1093 (48.3%) had received albumin treatment at least once. The overall 28-day mortality was 29.6%. After marginal structural modeling, daily albumin infusion was associated with a reduced risk of 28-day death (hazard ratio, 0.76; 95% CI 0.61-0.94). We found that patients benefit most from albumin infusion when initiated on the day of serum albumin concentration between 2.5 and 3.0 g/dL, serum lactate concentration greater than or equal to 2 mmol/L, MAP less than 60 mmHg, or vasopressor dosage between 0.2 and 0.3 mcg/kg/min (norepinephrine equivalent, NEE).
CONCLUSIONS: Albumin infusion is associated with a reduction in mortality in septic patients with liver cirrhosis under specific circumstances. Serum albumin concentration, serum lactate, MAP, and vasopressor dosage were found to be modifiers of treatment effectiveness and should be considered when deciding to initial albumin infusion.
参考来源
- Hu W, Chen H, Ma C, et al. Identification of indications for albumin administration in septic patients with liver cirrhosis. Crit Care. 2023. PMID: 37507790. doi:10.1186/s13054-023-04587-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。